Published in Proc Natl Acad Sci U S A on January 12, 2016
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci U S A (2016) 1.09
The Principles of Engineering Immune Cells to Treat Cancer. Cell (2017) 0.85
Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer. Angew Chem Int Ed Engl (2016) 0.82
CAR T Cell Therapy: A Game Changer in Cancer Treatment. J Immunol Res (2016) 0.81
New development in CAR-T cell therapy. J Hematol Oncol (2017) 0.78
A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy. J Hematol Oncol (2017) 0.77
Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials. Annu Rev Pathol (2016) 0.75
An oxygen sensitive self-decision making engineered CAR T-cell. Sci Rep (2017) 0.75
Engineering Chimeric Antigen Receptors. Acta Naturae (2017) 0.75
How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy. J Cell Physiol (2016) 0.75
Cancer: CARs: new models abound. Nat Rev Drug Discov (2016) 0.75
Driving better and safer HER2-specific CARs for cancer therapy. Oncotarget (2017) 0.75
A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members. Sci Rep (2017) 0.75
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 10.63
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13
Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21
Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med (2011) 7.82
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25
Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 6.14
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med (2014) 5.60
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80
Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol (1996) 4.45
THE CATABOLISM OF HOMOLOGOUS AND HETEROLOGOUS 7S GAMMA GLOBULIN FRAGMENTS. J Exp Med (1965) 3.87
Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci U S A (2000) 3.77
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther (2010) 3.29
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood (2012) 2.52
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood (2010) 2.52
Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science (2015) 2.50
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci U S A (2012) 1.99
Chimeric antigen receptor therapy for cancer. Annu Rev Med (2013) 1.94
Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther (2013) 1.89
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med (2015) 1.87
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res (2013) 1.85
PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med (2013) 1.76
Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol (2012) 1.71
The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res (2014) 1.69
Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J (2014) 1.64
Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood (2015) 1.52
Bispecific small molecule-antibody conjugate targeting prostate cancer. Proc Natl Acad Sci U S A (2013) 1.52
The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother (2005) 1.50
CAR T-cell therapy: toxicity and the relevance of preclinical models. Immunotherapy (2015) 1.45
CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS One (2013) 1.19
Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol Immunother (2010) 1.19
Structural basis of the CD8 alpha beta/MHC class I interaction: focused recognition orients CD8 beta to a T cell proximal position. J Immunol (2009) 1.18
A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res (2012) 1.15
Synthesis of bispecific antibodies using genetically encoded unnatural amino acids. J Am Chem Soc (2012) 1.14
T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res (2013) 1.14
Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting. Protein Eng (1997) 1.14
Protein conjugation with genetically encoded unnatural amino acids. Curr Opin Chem Biol (2013) 1.14
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci U S A (2016) 1.09
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia (2015) 1.09
High resolution structures of the 4-4-20 Fab-fluorescein complex in two solvent systems: effects of solvent on structure and antigen-binding affinity. Biophys J (1994) 1.07
Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther (2014) 1.06
Costimulation by CD137/4-1BB inhibits T cell apoptosis and induces Bcl-xL and c-FLIP(short) via phosphatidylinositol 3-kinase and AKT/protein kinase B. Eur J Immunol (2005) 1.00
T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res (2013) 0.98
Redirection of genetically engineered CAR-T cells using bifunctional small molecules. J Am Chem Soc (2015) 0.96
Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res (2012) 0.95
Adoptive T-cell therapy: adverse events and safety switches. Clin Transl Immunology (2014) 0.91
Multiformat T-cell-engaging bispecific antibodies targeting human breast cancers. Angew Chem Int Ed Engl (2015) 0.81
Lessons learned from a highly-active CD22-specific chimeric antigen receptor. Oncoimmunology (2013) 0.80